Volume 30, Issue 1 (1-2026)                   IBJ 2026, 30(1): 1-15 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Maroufi F, Ebrahimpour A, Davami F. Extracellular Vesicles-Derived MicroRNAs: Emerging Game Changers in Cancer Pathogenesis and Therapeutic Response. IBJ 2026; 30 (1) :1-15
URL: http://ibj.pasteur.ac.ir/article-1-5089-en.html
Extracellular Vesicles-Derived MicroRNAs: Emerging Game Changers in Cancer Pathogenesis and Therapeutic Response
Faezeh Maroufi , Amirali Ebrahimpour , Fatemeh Davami *
Abstract:  
Effective communication between cells is a fundamental feature of multicellular organisms, occurring through direct contact or the transfer of secreted molecules. Among these mediators, extracellular vesicles (EVs) function as biological messengers that transport bioactive molecules among cells. EVs are secreted by nearly all cell types. The interaction between tumor cells and EV components has been shown to influence various cancer-related processes, including proliferation, metastasis, stemness, chemoresistance, and immune modulation. Among the bioactive cargos of EVs, non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), play a significant role in shaping the tumor microenvironment. These EV-derived ncRNAs have emerged as promising tools for non-invasive diagnosis, prognosis, and therapeutic intervention across multiple cancer types. This review summarizes the current understanding of the functional roles of EV-derived miRNAs in cancer and highlights their potential clinical applications as novel biomarkers and therapeutic targets in cancer management.
Keywords: Extracellular vesicles, MicroRNAs, Neoplasms, Tumor microenvironment
Full-Text [PDF 1096 kb]      
Type of Study: Review Article | Subject: Cancer Biology
References
1. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010;78(9):838-48. [DOI:10.1038/ki.2010.278]
2. Jung MK, Mun JY. Sample preparation and imaging of exosomes by transmission electron microscopy. J Vis Exp. 2018;131:56482. [DOI:10.3791/56482]
3. Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. [DOI:10.1002/jev2.12451]
4. Li J, Zhang Y, Dong PY, Yang GM, Gurunathan S. A comprehensive review on the composition, biogenesis, purification, and multifunctional role of exosome as delivery vehicles for cancer therapy. Biomed Pharmacother. 2023:165:115087. [DOI:10.1016/j.biopha.2023.115087]
5. Wang X, Tian L, Lu J, Ng IO-L. Exosomes and cancer - diagnostic and prognostic biomarkers and therapeutic vehicle. Oncogenesis. 2022;11(1):54. [DOI:10.1038/s41389-022-00431-5]
6. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423-37. [DOI:10.1038/nm.3394]
7. Tai YL, Chen KC, Hsieh JT, Shen TL. Exosomes in cancer development and clinical applications. Cancer Sci. 2018;109(8):2364-74. [DOI:10.1111/cas.13697]
8. Yang N, Li S, Li G, Zhang S, Tang X, Ni S, et al. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget. 2017;8(2):3683-95. [DOI:10.18632/oncotarget.12465]
9. Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, et al. Exosomes: Key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5(1):145. [DOI:10.1038/s41392-020-00261-0]
10. Seo N, Shirakura Y, Tahara Y, Momose F, Harada N, Ikeda H, et al. Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells. Nat Commun. 2018;9(1):435. [DOI:10.1038/s41467-018-02865-1]
11. Liang G, Zhu Y, Ali DJ, Tian T, Xu H, Si K, et al. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J Nanobiotechnol. 2020;18(1):10. [DOI:10.1186/s12951-019-0563-2]
12. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):6977. [DOI:10.1126/science.aau6977]
13. Wang M, Zhou L, Yu F, Zhang Y, Li P, Wang K. The functional roles of exosomal long non-coding RNAs in cancer. Cell Mol Life Sci. 2019;76(11):2059-76. [DOI:10.1007/s00018-019-03018-3]
14. Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021;65(4):625-39. [DOI:10.1042/EBC20200032]
15. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5-18. [DOI:10.1038/nrc.2017.99]
16. Wu S, Mu C, Sun JJ, Hu XR, Yao YH. Role of exosomal non-coding RNA in the tumour microenvironment of genitourinary system tumours. Technol Cancer Res Treat. 2023:22:15330338231198348. [DOI:10.1177/15330338231198348]
17. Sheta M, Taha EA, Lu Y, Eguchi T. Extracellular vesicles: New classification and tumor immunosuppression. Biology. 2023;12(1):110. [DOI:10.3390/biology12010110]
18. Lakkaraju A, Rodriguez-Boulan E. Itinerant exosomes: Emerging roles in cell and tissue polarity. Trends Cell Biol. 2008;18(5):199-209. [DOI:10.1016/j.tcb.2008.03.002]
19. Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. 2013;126(Pt 24):5553-65. [DOI:10.1242/jcs.128868]
20. Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: Small particle, big player. J Hematol Oncol. 2015;8(1):83. [DOI:10.1186/s13045-015-0181-x]
21. Boura E, Ivanov V, Carlson LA, Mizuuchi K, Hurley JH. Endosomal sorting complex required for transport (ESCRT) complexes induce phase-separated microdomains in supported lipid bilayers. J Biol Chem. 2012;287(33):28144-51. [DOI:10.1074/jbc.M112.378646]
22. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319(5867):1244-7. [DOI:10.1126/science.1153124]
23. Schmidt O, Teis D. The ESCRT machinery. Curr Biol. 2012;22(4):116-20. [DOI:10.1016/j.cub.2012.01.028]
24. Christ L, Raiborg C, Wenzel EM, Campsteijn C, Stenmark H. Cellular functions and molecular mechanisms of the ESCRT membrane-scission machinery. Trends Biochem Sci. 2017;42(1):42-56. [DOI:10.1016/j.tibs.2016.08.016]
25. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012;14(7):677-85. [DOI:10.1038/ncb2502]
26. Krylova SV, Feng D. The machinery of exosomes: Biogenesis, release, and uptake. Int J Mol Sci. 2023;24(2):1337. [DOI:10.3390/ijms24021337]
27. Xie F, Zhou X, Fang M, Li H, Su P, Tu Y, et al. Extracellular vesicles in cancer immune microenvironment and cancer immunotherapy. Adv Sci. 2019;6(24):1901779. [DOI:10.1002/advs.201901779]
28. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-9. [DOI:10.1038/ncb1596]
29. Zomer A, Maynard C, Verweij FJ, Kamermans A, Schäfer R, Beerling E, et al. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 2015;161(5):1046-57. [DOI:10.1016/j.cell.2015.04.042]
30. Li S, Li Y, Chen B, Zhao J, Yu S, Tang Y, et al. exoRBase: A database of circRNA, lncRNA and mRNA in human blood exosomes. Nucleic Acids Res. 2018;46(1):106-12. [DOI:10.1093/nar/gkx891]
31. Zheng D, Huo M, Li B, Wang W, Piao H, Wang Y, et al. The role of exosomes and exosomal microRNA in cardiovascular disease. Front Cell Dev Biol. 2021:8:616161. [DOI:10.3389/fcell.2020.616161]
32. Yuen JG, Hwang G-R, Fesler A, Intriago E, Pal A, Ojha A, et al. Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma. Mol Ther Oncol. 2024;32(1):200769. [DOI:10.1016/j.omton.2024.200769]
33. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA. 2010;107(14):6328-33. [DOI:10.1073/pnas.0914843107]
34. Wang W, Wang T, Zhang Y, Deng T, Zhang H, Ba YI. Gastric cancer secreted miR-214-3p inhibits the anti-angiogenesis effect of apatinib by suppressing ferroptosis in vascular endothelial cells. Oncol Res. 2024; 32(3):489-502. [DOI:10.32604/or.2023.046676]
35. Dilsiz N. Role of exosomes and exosomal microRNAs in cancer. Future Sci OA. 2020;6(4):465. [DOI:10.2144/fsoa-2019-0116]
36. Donoso-Quezada J, Ayala-Mar S, González-Valdez J. The role of lipids in exosome biology and intercellular communication: Function, analytics and applications. Traffic. 2021;22(7):204-20. [DOI:10.1111/tra.12803]
37. Kumar VBS, Anjali K. Tumour generated exosomal miRNAs: A major player in tumour angiogenesis. Biochim Biophys Acta Mol Basis Dis. 2022;1868(6):166383. [DOI:10.1016/j.bbadis.2022.166383]
38. Si G, Chen X, Li Y, Yuan X. Exosomes promote pre-metastatic niche formation in colorectal cancer. Heliyon. 2024;10(6):27572. [DOI:10.1016/j.heliyon.2024.e27572]
39. Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol Oncol. 2019;12(1):84. [DOI:10.1186/s13045-019-0772-z]
40. Kumar S, Gomez EC, Chalabi-Dchar M, Rong C, Das S, Ugrinova I, et al. Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low levels of nucleolin. Sci Rep. 2017;7(1):9017. [DOI:10.1038/s41598-017-09353-4]
41. Otmani K, Rouas R, Lagneaux L, Krayem M, Duvillier H, Berehab M, et al. Acute myeloid leukemia-derived exosomes deliver miR-24-3p to hinder the T-cell immune response through DENN/MADD targeting in the NF-κB signaling pathways. Cell Commun Signal. 2023;21(1):253. [DOI:10.1186/s12964-023-01259-1]
42. Wang L, Zhao F, Xiao Z, Yao L. Exosomal microRNA-205 is involved in proliferation, migration, invasion, and apoptosis of ovarian cancer cells via regulating VEGFA. Cancer Cell Int. 2019;19(1):281. [DOI:10.1186/s12935-019-0990-z]
43. Yang F, Ning Z, Ma L, Liu W, Shao C, Shu Y, et al. Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts. Mol Cancer. 2017;16(1):148. [DOI:10.1186/s12943-017-0718-4]
44. Zhao S, Mi Y, Guan B, Zheng B, Wei P, Gu Y, et al. Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer. J Hematol Oncol. 2020;13(1):156. [DOI:10.1186/s13045-020-00991-2]
45. Zhang X, Shi H, Yuan X, Jiang P, Qian H, Xu W. Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol Cancer. 2018;17(1):146. [DOI:10.1186/s12943-018-0898-6]
46. Song W, Chen Y, Zhu G, Xie H, Yang Z, Li L. Exosome-mediated miR-9-5p promotes proliferation and migration of renal cancer cells both in vitro and in vivo by targeting SOCS4. Biochem Biophys Res Commun. 2020;529(4):1216-24. [DOI:10.1016/j.bbrc.2020.06.114]
47. Jiang Y, Qiu Q, Jing X, Song Z, Zhang Y, Wang C, et al. Cancer-associated fibroblast-derived exosome miR-181b-3p promotes the occurrence and development of colorectal cancer by regulating SNX2 expression. Biochem Biophys Res Commun. 2023:641:177-185. [DOI:10.1016/j.bbrc.2022.12.026]
48. Yan T, Wang X, Wei G, Li H, Hao L, Liu Y, et al. Exosomal miR-10b-5p mediates cell communication of gastric cancer cells and fibroblasts and facilitates cell proliferation. J Cancer. 2021;12(7):2140-50. [DOI:10.7150/jca.47817]
49. Zhou Y, Zhang Y, Xu J, Wang Y, Yang Y, Wang W, et al. Schwann cell-derived exosomes promote lung cancer progression via miRNA-21-5p. Glia. 2024;72(4):692-707. [DOI:10.1002/glia.24497]
50. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: A hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28. [DOI:10.1038/s41392-020-0134-x]
51. Jiang Q, Tan X-P, Zhang C-H, Li Z-Y, Li D, Xu Y, et al. Non-coding RNAs of extracellular vesicles: Key players in organ-specific metastasis and clinical implications. Cancers. 2022;14(22):5693. [DOI:10.3390/cancers14225693]
52. Allgayer H, Mahapatra S, Mishra B, Swain B, Saha S, Khanra S, et al. Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: The status quo of methods and experimental models 2025. Mol Cancer. 2025;24(1):167. [DOI:10.1186/s12943-025-02338-2]
53. Wu B, Sun D, Ma L, Deng Y, Zhang S, Dong L, et al. Exosomes isolated from CAPS1 overexpressing colorectal cancer cells promote cell migration. Oncol Rep. 2019;42(6):2528-36. [DOI:10.3892/or.2019.7361]
54. Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18(1):91. [DOI:10.1186/s12943-019-1019-x]
55. Kan JY, Shih SL, Yang SF, Chu -Y, Chen FM, Li CL, et al. Exosomal microRNA-92b is a diagnostic biomarker in breast cancer and targets survival-related MTSS1L to promote tumorigenesis. Int J Mol Sci. 2024;25(2):1295. [DOI:10.3390/ijms25021295]
56. Yu My, Jia Hj, Zhang J, Ran Gh, Liu Y, Yang Xh. Exosomal miRNAs-mediated macrophage polarization and its potential clinical application. Int Immunopharmacol. 2023:117:109905. [DOI:10.1016/j.intimp.2023.109905]
57. Gou Z, Li J, Liu J, Yang N. The hidden messengers: Cancer associated fibroblasts-derived exosomal miRNAs as key regulators of cancer malignancy. Front Cell Dev Biol. 2024:12:1378302. [DOI:10.3389/fcell.2024.1378302]
58. Bayat M, Sadri Nahand J. Exosomal miRNAs: The tumor's trojan horse in selective metastasis. Mol Cancer. 2024;23(1):167. [DOI:10.1186/s12943-024-02081-0]
59. Mu Y, Yang M, Liu J, Yao Y, Sun H, Zhuang J. Exosomes in hypoxia: Generation, secretion, and physiological roles in cancer progression. Front Immunol. 2025:16:1537313. [DOI:10.3389/fimmu.2025.1537313]
60. Tan S, Xia L, Yi P, Han Y, Tang L, Pan Q, et al. Exosomal miRNAs in tumor microenvironment. J Exp Clin Cancer Res. 2020;39(1):67. [DOI:10.1186/s13046-020-01570-6]
61. Zhao S, Mi Y, Zheng B, Wei P, Gu Y, Zhang Z, et al. Highly-metastatic colorectal cancer cell released miR-181a-5p-rich extracellular vesicles promote liver metastasis by activating hepatic stellate cells and remodelling the tumour microenvironment. J Extracell Vesicles. 2022;11(1):12186. [DOI:10.1002/jev2.12186]
62. Zhang X, Sai B, Wang F, Wang L, Wang Y, Zheng L, et al. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. Mol Cancer. 2019;18(1):40. [DOI:10.1186/s12943-019-0959-5]
63. Shi W, Liu Y, Qiu X, Yang L, Lin G. Cancer-associated fibroblasts-derived exosome-mediated transfer of miR-345-5p promotes the progression of colorectal cancer by targeting CDKN1A. Carcinogenesis. 2023;44(4):317-27. [DOI:10.1093/carcin/bgad014]
64. Xia X, Wang S, Ni B, Xing S, Cao H, Zhang Z, et al. Hypoxic gastric cancer-derived exosomes promote progression and metastasis via MiR-301a-3p/PHD3/HIF-1α positive feedback loop. Oncogene. 2020;39(39):6231-44. [DOI:10.1038/s41388-020-01425-6]
65. Zhang Y, Lai X, Yue Q, Cao F, Zhang Y, Sun Y, et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-16-5p restrains epithelial-mesenchymal transition in breast cancer cells via EPHA1/NF-κB signaling axis. Genomics. 2022;114(3):110341. [DOI:10.1016/j.ygeno.2022.110341]
66. Zhang Y, Tedja R, Millman M, Wong T, Fox A, Chehade H, et al. Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells. J Ovarian Res. 2023;16(1):233. [DOI:10.1186/s13048-023-01312-0]
67. Tiong TY, Chan ML, Wang CH, Yadav VK, Pikatan NW, Fong I-H, et al. Exosomal miR-21 determines lung-to-brain metastasis specificity through the DGKB/ERK axis within the tumor microenvironment. Life Sci. 2023:329:121945. [DOI:10.1016/j.lfs.2023.121945]
68. Liu ZL, Chen H-H, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198. [DOI:10.1038/s41392-023-01460-1]
69. Liang Z, Zhang Y, Huang C, Yan Z, Miao H. Tumor-derived exosomes promote the angiogenic function of vascular endothelial cells by activating the miR-423-5p/EFNA3 signaling pathway. J Biomed Nanotechnol. 2024;20(5):887-94. [DOI:10.1166/jbn.2024.3833]
70. Chen J, Ding C, Yang X, Zhao J. BMSCs-derived exosomal MiR-126-3p inhibits the viability of NSCLC cells by targeting PTPN9. J Buon. 2021;26(5):1832-41.
71. Yang X, Wu M, Kong X, Wang Y, Hu C, Zhu D, et al. Exosomal miR-3174 induced by hypoxia promotes angiogenesis and metastasis of hepatocellular carcinoma by inhibiting HIPK3. iScience. 2024;27(2):108955. [DOI:10.1016/j.isci.2024.108955]
72. Yang W, Tan S, Yang L, Chen X, Yang R, Oyang L, et al. Exosomal miR-205-5p enhances angiogenesis and nasopharyngeal carcinoma metastasis by targeting desmocollin-2. Mol Ther Oncolytics. 2022:24:612-23. [DOI:10.1016/j.omto.2022.02.008]
73. Liu Z, Du D, Zhang S. Tumor-derived exosomal miR-1247-3p promotes angiogenesis in bladder cancer by targeting FOXO1. Cancer Biol Ther. 2024;25(1):2290033. [DOI:10.1080/15384047.2023.2290033]
74. Zhou X, Yan T, Huang C, Xu Z, Wang L, Jiang E, et al. Melanoma cell-secreted exosomal miR-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway. J Exp Clin Cancer Res. 2018;37(1):242. [DOI:10.1186/s13046-018-0911-3]
75. Wang H, Wang L, Zhou X, Luo X, Liu K, Jiang E, et al. OSCC exosomes regulate miR-210-3p targeting EFNA3 to promote oral cancer angiogenesis through the PI3K/AKT pathway. Biomed Res Int. 2020:2020:2125656. [DOI:10.1155/2020/2125656]
76. Almouh M, Pakravan K, Ghazimoradi MH, Motamed R, Bakhshinejad B, Hassan ZM, et al. Exosomes released by oxidative stress-induced mesenchymal stem cells promote murine mammary tumor progression through activating the STAT3 signaling pathway. Mol Cell Biochem. 2024;479(12):3375-91. [DOI:10.1007/s11010-024-04934-0]
77. Hsu YL, Hung JY, Chang W-A, Lin YS, Pan YC, Tsai PH, et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 2017;36(34):4929-42. [DOI:10.1038/onc.2017.105]
78. Zhang J, Pan Y, Jin L, Yang H, Cao P. Exosomal-miR-522-3p derived from cancer-associated fibroblasts accelerates tumor metastasis and angiogenesis via repression bone morphogenetic protein 5 in colorectal cancer. J Gastroenterol Hepatol. 2024;39(1):107-20. [DOI:10.1111/jgh.16345]
79. He Q, Ye A, Ye W, Liao X, Qin G, Xu Y, et al. Cancer-secreted exosomal miR-21-5p induces angiogenesis and vascular permeability by targeting KRIT1. Cell Death Dis. 2021;12(6):576. [DOI:10.1038/s41419-021-03803-8]
80. Chen S, Chen X, Luo Q, Liu X, Wang X, Cui Z, et al. Retinoblastoma cell-derived exosomes promote angiogenesis of human vesicle endothelial cells through microRNA-92a-3p. Cell Death Dis. 2021;12(7):695. [DOI:10.1038/s41419-021-03986-0]
81. Balaraman AK, Arockia Babu M, Afzal M, Sanghvi G, M MR, Gupta S, et al. Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells. Regen Ther. 2025:28:558-72. [DOI:10.1016/j.reth.2025.01.019]
82. Ren W, Zhang X, Li W, Feng Q, Feng H, Tong Y, et al. Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer. Cancer Manag Res. 2019:11:4023-40. [DOI:10.2147/CMAR.S198886]
83. Wang B, Cheng D, Ma D, Chen R, Li D, Zhao W, et al. Mutual regulation of PD-L1 immunosuppression between tumor-associated macrophages and tumor cells: A critical role for exosomes. Cell Commun Signal. 2024;22(1):21. [DOI:10.1186/s12964-024-01473-5]
84. Choi JY, Seok HJ, Lee DH, Lee E, Kim T-J, Bae S, et al. Tumor-derived miR-67945-p enhances cancer growth by promoting M2 macrophage polarization. Cell Commun Signal. 2024;22(1):190. [DOI:10.1186/s12964-024-01570-5]
85. Qiu S, Xie L, Lu C, Gu C, Xia Y, Lv J, et al. Gastric cancer-derived exosomal miR-519a-3p promotes liver metastasis by inducing intrahepatic M2-like macrophage-mediated angiogenesis. J Exp Clin Cancer Res. 2022;41(1):296. [DOI:10.1186/s13046-022-02499-8]
86. Ying X, Wu Q, Wu X, Zhu Q, Wang X, Jiang L, et al. Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 2016;7(28):43076-87. [DOI:10.18632/oncotarget.9246]
87. Hu Z, You L, Hu S, Yu L, Gao Y, Li L, et al. Hepatocellular carcinoma cell-derived exosomal miR-21-5p promotes the polarization of tumor-related macrophages (TAMs) through SP1/XBP1 and affects the progression of hepatocellular carcinoma. Int Immunopharmacol. 2024:126:111149. [DOI:10.1016/j.intimp.2023.111149]
88. Liu W, Long Q, Zhang W, Zeng D, Hu B, Liu S, et al. miRNA-221-3p derived from M2-polarized tumor-associated macrophage exosomes aggravates the growth and metastasis of osteosarcoma through SOCS3/JAK2/STAT3 axis. Aging. 2021;13(15):19760-75. [DOI:10.18632/aging.203388]
89. Hao C, Sheng Z, Wang W, Feng R, Zheng Y, Xiao Q, et al. Tumor-derived exosomal miR-148b-3p mediates M2 macrophage polarization via TSC2/mTORC1 to promote breast cancer migration and invasion. Thorac Cancer. 2023;14(16):1477-91. [DOI:10.1111/1759-7714.14891]
90. Xun J, Du L, Gao R, Shen L, Wang D, Kang L, et al. Cancer-derived exosomal miR-138-5p modulates polarization of tumor-associated macrophages through inhibition of KDM6B. Theranostics. 2021;11(14):6847-59. [DOI:10.7150/thno.51864]
91. Huang ZM, Wang H, Ji ZG. Bladder mesenchymal stromal cell-derived exosomal miRNA-217 modulates bladder cancer cell survival through Hippo-YAP pathway. Inflamm Res. 2021;70(9):959-69. [DOI:10.1007/s00011-021-01494-7]
92. Yao X, Tu Y, Xu Y, Guo Y, Yao F, Zhang X. Endoplasmic reticulum stress‐induced exosomal miR‐27a‐3p promotes immune escape in breast cancer via regulating PD‐L1 expression in macrophages. J Cell Mol Med. 2020;24(17):9560-73. [DOI:10.1111/jcmm.15367]
93. Yin Y, Liu B, Cao Y, Yao S, Liu Y, Jin G, et al. Colorectal cancer‐derived small extracellular vesicles promote tumor immune evasion by upregulating PD‐L1 expression in tumor‐associated macrophages. Adv Sci. 2022;9(9):2102620. [DOI:10.1002/advs.202102620]
94. Wang H, Huang H, Wang L, Liu Y, Wang M, Zhao S, et al. Cancer-associated fibroblasts secreted miR-103a-3p suppresses apoptosis and promotes cisplatin resistance in non-small cell lung cancer. Aging. 2021;13(10):14456-68. [DOI:10.18632/aging.103556]
95. Yang Z, Zhao N, Cui J, Wu H, Xiong J, Peng T. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Cell Oncol. 2020;43(1):123-36. [DOI:10.1007/s13402-019-00476-6]
96. Zhao S, Pan T, Deng J, Cao L, Vicencio JM, Liu J, et al. Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer. Br J Cancer. 2023;128(4):665-77. [DOI:10.1038/s41416-022-02077-x]
97. Fang Y, Zhou W, Rong Y, Kuang T, Xu X, Wu W, et al. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Exp Cell Res. 2019;383(1):111543. [DOI:10.1016/j.yexcr.2019.111543]
98. You M, Xie Z, Zhang N, Zhang Y, Xiao D, Liu S, et al. Signaling pathways in cancer metabolism: Mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):196. [DOI:10.1038/s41392-023-01442-3]
99. Deng Y, Ding H, Zhang Y, Feng X, Ye Q, Tian R, et al. TP53 mitigates cisplatin resistance in non-small cell lung cancer by mediating the effects of resistant cell-derived exosome mir-424-5p. Heliyon. 2024;10(5):26853. [DOI:10.1016/j.heliyon.2024.e26853]
100. Mao X, Peng S, Lu Y, Song L. Regulatory functions of microRNAs in cancer stem cells: Mechanism, facts, and perspectives. Cells. 2025;14(14):1073. [DOI:10.3390/cells14141073]
101. Yang Q, Zhao S, Shi Z, Cao L, Liu J, Pan T, et al. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling. J Exp Clin Cancer Res. 2021;40(1):120. [DOI:10.1186/s13046-021-01901-1]
102. Ning T, Li J, He Y, Zhang H, Wang X, Deng T, et al. Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer. Mol Ther. 2021;29(9):2723-36. [DOI:10.1016/j.ymthe.2021.04.028]
103. Cui HY, Rong JS, Chen J, Guo J, Zhu JQ, Ruan M, et al. Exosomal microRNA-588 from M2 polarized macrophages contributes to cisplatin resistance of gastric cancer cells. World J Gastroenterol. 2021;27(36):6079-92. [DOI:10.3748/wjg.v27.i36.6079]
104. Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat. 2014;147(2):423-31. [DOI:10.1007/s10549-014-3037-0]
105. Zhuang L, Zhang B, Liu X, Lin L, Wang L, Hong Z, et al. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1. Cell Biol Int. 2021;45(10):2140-9. [DOI:10.1002/cbin.11671]
106. Binenbaum Y, Fridman E, Yaari Z, Milman N, Schroeder A, Ben David G, et al. Transfer of miRNA in macrophage-derived exosomes induces drug resistance in pancreatic adenocarcinoma. Cancer Res. 2018;78(18):5287-99. [DOI:10.1158/0008-5472.CAN-18-0124]
107. Ouyang YX, Feng J, Wang Z, Zhang GJ, Chen M. miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα. Mol Biomed. 2021;2(1):20. [DOI:10.1186/s43556-021-00045-0]
108. Bayat H, Pourgholami MH, Rahmani S, Pournajaf S, Mowla SJ. Synthetic miR-21 decoy circularized by tRNA splicing mechanism inhibited tumorigenesis in glioblastoma in vitro and in vivo models. Mol Ther Nucleic Acids. 2023:32:432-44. [DOI:10.1016/j.omtn.2023.04.001]
109. Adibzadeh S, Amiri S, Barkhordari F, Mowla SJ, Bayat H, Ghanbari S, et al. CHO cell engineering via targeted integration of circular miR-21 decoy using CRISPR/RMCE hybrid system. Appl Microbiol Biotechnol. 2024;108(1):434. [DOI:10.1007/s00253-024-13266-4]
110. Hei YY, Wang S, Xi XX, Wang HP, Guo Y, Xin M, et al. Design, synthesis, and evaluation of fluoroquinolone derivatives as microRNA-21 small-molecule inhibitors. J Pharm Anal. 2022;12(4):653-63. [DOI:10.1016/j.jpha.2021.12.008]
111. Menon A, Abd-Aziz N, Khalid K, Poh CL, Naidu R. miRNA: A promising therapeutic target in cancer. Int J Mol Sci. 2022;23(19):11502. [DOI:10.3390/ijms231911502]
112. Li J, Chen J, Wang S, Li P, Zheng C, Zhou X, et al. Blockage of transferred exosome-shuttled miR-494 inhibits melanoma growth and metastasis. J Cell Physiol. 2019;234(9):15763-74. [DOI:10.1002/jcp.28234]
113. Zhang K, Dong C, Chen M, Yang T, Wang X, Gao Y, et al. Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma. Theranostics. 2020;10(1):411-25. [DOI:10.7150/thno.33482]
114. Ruan Q, Wang C, Wu Y, Zhu Q. Exosome microRNA-22 inhibiting proliferation, migration and invasion through regulating Twist1/CADM1 axis in osteosarcoma. Sci Rep. 2024;14(1):761. [DOI:10.1038/s41598-023-50612-4]
115. Song B, Hou G, Xu M, Chen M. Exosomal miR-122-3p represses the growth and metastasis of MCF-7/ADR cells by targeting GRK4-mediated activation of the Wnt/β-catenin pathway. Cell Signal. 2024:117:111101. [DOI:10.1016/j.cellsig.2024.111101]
116. Zhang B, Yang Y, Tao R, Yao C, Zhou Z, Zhang Y. Exosomes loaded with miR-665 inhibit the progression of osteosarcoma in vivo and in vitro. Am J Transl Res. 2022;14(10):7012-26.
117. Han B, Huang J, Han Y, Hao J, Wu X, Song H, et al. The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin. Int J Biol Macromol. 2019:125:544-56. [DOI:10.1016/j.ijbiomac.2018.12.075]
118. Wang J, Wang C, Li Y, Li M, Zhu T, Shen Z, et al. Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer. Clin Transl Med. 2021;11(5):425. [DOI:10.1002/ctm2.425]
119. Xu Y, Shen L, Li F, Yang J, Wan X, Ouyang M. microRNA-16-5p-containing exosomes derived from bone marrow-derived mesenchymal stem cells inhibit proliferation, migration, and invasion, while promoting apoptosis of colorectal cancer cells by downregulating ITGA2. J Cell Physiol. 2019;234(11):21380-94. [DOI:10.1002/jcp.28747]
120. Ning S, Chen Y, Li S, Liu M, Liu H, Ye M, et al. Exosomal miR-99b-5p secreted from mesenchymal stem cells can retard the progression of colorectal cancer by targeting FGFR3. Stem Cell Rev Rep. 2023;19(8):2901-17. [DOI:10.1007/s12015-023-10606-1]
121. Wang L, Hu YY, Zhao JL, Huang F, Liang SQ, Dong L, et al. Targeted delivery of miR-99b reprograms tumor-associated macrophage phenotype leading to tumor regression. J Immunother Cancer. 2020;8(2):517. [DOI:10.1136/jitc-2019-000517]
122. He Z, Li W, Zheng T, Liu D, Zhao S. Human umbilical cord mesenchymal stem cells-derived exosomes deliver microRNA-375 to downregulate ENAH and thus retard esophageal squamous cell carcinoma progression. J Exp Clin Cancer Res. 2020;39(1):140. [DOI:10.1186/s13046-020-01631-w]
123. Lang FM, Hossain A, Gumin J, Momin EN, Shimizu Y, Ledbetter D, et al. Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. Neuro Oncol. 2018;20(3):380-90. [DOI:10.1093/neuonc/nox152]
124. Liu B, Zhang R, Zhu Y, Hao R. Exosome-derived microRNA-433 inhibits tumorigenesis through incremental infiltration of CD4 and CD8 cells in non-small cell lung cancer. Oncol Lett. 2021;22(2):607. [DOI:10.3892/ol.2021.12868]
125. Wu H, Liu C, Yang Q, Xin C, Du J, Sun F, et al. MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4. Autophagy. 2020;16(4):683-97. [DOI:10.1080/15548627.2019.1635380]
126. Li Z, Suo B, Long G, Gao Y, Song J, Zhang M, et al. Exosomal miRNA-16-5p derived from M1 macrophages enhances T cell-dependent immune response by regulating PD-L1 in gastric cancer. Front Cell Dev Biol. 2020:8:572689. [DOI:10.3389/fcell.2020.572689]
127. Chen H-L, Luo YP, Lin MW, Peng XX, Liu ML, Wang YC, et al. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression. Cancer Med. 2022;11(13):2627-43. [DOI:10.1002/cam4.4638]
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb